Here’s what you should know:
1. Contingent on the approval of a U.S. state judge, Pershing Square will pay Allergan’s investors $193.75 million and Valeant will pay the remaining $96.25 million.
2. Pershing Square Holdings manager Bill Ackman said the companies decided to settle the lawsuit, “in the best interest of our investors.”
3. Allergan investors brought the suit against Valeant and Pershing Square Holdings after discovering Mr. Ackman had bought a large portion of Allergan’s shares knowing Valeant was submitting a bid to acquire Allergan.
4. Mr. Ackman made more than $2 billion on his initial investment in Allergan. He followed up that investment with subsequent investments, eventually losing $4.2 billion.
More articles on supply chain:
Medline awarded OneBlood distribution agreement — 3 insights
These 3 trends will rock the pharmaceutical advertising industry in 2018
8 statistics on ASC drug and medical supply cost per OR across the US
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.